Halozyme Therapeutics (HALO) : Traders are bullish on Halozyme Therapeutics (HALO) as it has outperformed the S&P 500 by a wide margin of 22.52% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 18.45%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 19.09% in the last 1 week, and is up 20.04% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The stock has recorded a 20-day Moving Average of 17.44% and the 50-Day Moving Average is 21.48%.The 200 Day SMA reached 14.48% Halozyme Therapeutics, Inc. is up 40.61% in the last 3-month period. Year-to-Date the stock performance stands at -30.87%.
Halozyme Therapeutics (HALO) has been rated by 3 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $16 and the lowest price target forecast is $7. The average forecast of all the analysts is $12.58 and the expected standard deviation is $5.08.
For the current week, the company shares have a recommendation consensus of Buy. Halozyme Therapeutics (NASDAQ:HALO): The stock opened at $11.24 and touched an intraday high of $12.06 on Friday. During the day, the stock corrected to an intraday low of $11.13, however, the bulls stepped in and pushed the price higher to close in the green at $11.98 with a gain of 7.93% for the day. The total traded volume for the day was 4,049,500. The stock had closed at $11.98 in the previous trading session.
Halozyme Therapeutics, Inc. is a biotechnology company, which is focused on developing and commercializing oncology therapies that target the tumor microenvironment. The Companys development pipeline consists primarily of clinical-stage product candidates in oncology and diabetes. The product candidates in its pipeline are based on rHuPH20, a human recombinant hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid (HA). Its lead oncology program is PEGPH20 (PEGylated recombinant human hyaluronidase), a new molecular entity, under development for the systemic treatment of tumors that accumulate HA. The Company is in collaboration with pharmaceutical companies including, Roche, Pfizer, Janssen and Baxter for its drug delivery platform, ENHANZE, which enables biologics and small molecule compounds that are administered intravenously to be delivered subcutaneously.